Evidence map›Paper›PMID 32988758›Full record

ReviewDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2021

COVID 19 and liver: An A-Z literature review.

Marwa Ibrahim Metawea, Walid Ibrahim Yousif, Islam Moheb

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Hepatic involvement in major respiratory viral infections.Clinical and experimental hepatology · 2025
    Review
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. COVID-19 and liver injury in individuals with obesity.World journal of gastroenterology · 2023
    Review
  16. Review
  17. Liver Injury in Patients with COVID-19: A Retrospective Study.International journal of medical sciences · 2023
    Article
  18. Article
  19. Observational
  20. Liver injury induced by COVID 19 treatment - what do we know?World journal of gastroenterology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Marwa Ibrahim MetaweaMD. Hepatology department, Faculty of Medicine, Alexandria University, Egypt.
Walid Ibrahim YousifMD. Hepatology department, Faculty of Medicine, Alexandria University, Egypt. Electronic address: docwalido@hotmail.com.
Islam MohebMD. Hepatology department, Faculty of Medicine, Alexandria University, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus pandemic has changed the priorities of the whole medical society. During the clinical course of COVID-19, it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. In this literature review, we summarize the most recent studies, which covered the pathophysiology of COVID-19 induced liver injury including; hepatic pathological findings, therapy related liver damage, and the effects of the viral infection on pre-existing liver diseasesin context of the most recent recommendations. Conclusions: This review sheds light on the impact of COVID-19 infection on the liver, as well as the prognostic effect of liver laboratory markers on disease outcome. Temporal variations in liver parameters during disease course as well as different patterns of derangement are depicted. More intensive surveillance and individualized therapeutic approaches should be tailored for immunocompromised patients with advanced liver disease, hepatocellular carcinoma, and liver transplant patients. Despite the limited studies on COVID-19 infected patients with preexisting liver disease, this comprehensive overview provides a perspective on the management of liver disease during COVID-19.

Indexed as

COVID-19COVID-19 Drug TreatmentLiverLiver DiseasesAntiviral AgentsChemical and Drug Induced Liver InjuryHumansLiver Function TestsPatient Care ManagementPrognosisSARS-CoV-2Antiviral AgentsCovid -19Drug hepatotoxicityInflammatory responseLiver functionLiver pathology

Identifiers

PMID32988758
PMCPMC7494329
OpenAlexW3087845861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.